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The impact of being homeless on the
unsuccessful outcome of treatment of
pulmonary TB in São Paulo State, Brazil
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Abstract
Background: Tuberculosis (TB) is a major public health problem requiring complex treatment, the success of which
depends on biological, social, and institutional factors. São Paulo State (SPS), in Brazil, has a high TB burden. Because
of high socioeconomic heterogeneity and chaotic urbanisation, homelessness might play an important role in the TB
burden in SPS. Our aim was to determine the association between homelessness and outcome of treatment of
pulmonary TB (PTB) in SPS.
Methods: A historical cohort from the routine SPS TB database for 2009-2013 was analysed. The study population was
newly diagnosed adult patients with PTB. Homelessness was ascertained at notification or when treatment started. Our
outcome was unsuccessful outcome of treatment. We used logistic regression to adjust for potential confounders and
multiple imputation for missing data.
Results: We analysed 61,817 patients; 1726 (2.8 %, 95%CI 2.7-2.9 %) were homeless. Homeless patients were
concentrated in bigger cities, were more frequently middle-aged males, had black/brown skin colour, and had
received less education (P < 0.001, for all). Alcohol and drug use was three times more frequent in homeless
patients (43.2 % vs 14.4 %, 30.2 % vs. 9.4 %, P < 0.001, respectively). HIV testing was less common among the
homeless, of whom 17.3 % were HIV positive compared with 8.5 % among the not homeless population
(P < 0.001). Microbiologic confirmation was more frequent among the homeless (91.6 % vs. 84.8 %, P < 0.001).
Unsuccessful outcome of treatment was 57.3 % among the homeless and 17.5 % among the not homeless
(OR = 6.32, 95%CI 5.73-6.97, P < 0.001), mainly due to loss to follow-up (39 %) and death (10.5 %). After full-adjustment
for potential confounders, homelessness remained strongly associated with lower treatment success (aOR = 4.96, 95 %
CI 4.27-5.76, P < 0.001). HIV status interacted with homelessness: among HIV-infected patients, the aOR was 2.45 (95%CI
1.90-3.16, Pinteraction < 0.001). The population attributable fraction for the joint effect of homelessness, alcohol and drug
use was almost 20 %.
Conclusions: Confirming our hypothesis, homelessness led to a marked reduction in the successful treatment of newly
diagnosed pulmonary tuberculosis. Homelessness and associated conditions were important contributors to lack of
treatment success in pulmonary tuberculosis in São Paulo. A multifaceted intervention must be implemented to target
this vulnerable population.
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Background
Tuberculosis (TB) is an ancient infectious disease that
poses several challenges from both the individual and
the societal perspective [1]. The 2015 World Health
Organization (WHO) report estimated 9.6 million new
TB cases and 1.5 million TB deaths worldwide [2].
Although improvements in the burden of TB have been
observed, several barriers to TB control remain [1–3].
Pulmonary TB (PTB) is the most frequent TB presenta-
tion, representing 80-85 % of cases [1]. PTB treatment re-
quires prolonged and complex management [4]. Although
there has been research on shorter treatment courses and
alternative schemes, their use in clinical practice is still in
debate [5]. Several factors influence treatment adherence,
from high incidence of adverse drug events, to direct/
indirect associated costs and stigmatization [3, 6–8].
Regarding TB treatment outcomes, some risk factors
have been associated with unsuccessful outcome of
treatment, such as: age [9–12], male gender [9, 13], race
[10], being an immigrant [10], illiteracy [14], malnutri-
tion [12], HIV positivity [9, 12, 14–17], chronic comor-
bidities [12, 13, 18], and socioeconomic factors [12, 16].
Some factors such as diabetes mellitus and smoking
have been associated more frequently with relapse,
treatment failure, and death [12, 19–21], while drug use
and alcohol use were associated with loss to follow-up
and death [15, 19]. Delay in diagnosis and treatment
are also fundamental issues [9, 18, 22].
TB has been labelled a disease of poverty and health
inequalities [3, 23]. Homelessness is likely to be an
extreme life condition, encompassing several vulnerabil-
ities that markedly increase the risk of being infected,
having latent TB infection (LTBI) and developing active
disease. Indeed, the homeless population has 10 to 85
times higher incidence of LTBI and active TB compared
to the general population [24–26]. Homeless patients
are also the source of TB outbreaks in shelters [27]. PTB
among the homeless is usually highly infectious, due to
the high burden of Mycobacterium tuberculosis in their
sputum, delayed diagnosis and overcrowding [28]. These
facts highlight the importance of a dedicated and multi-
disciplinary approach to these patients. However, there
is a lack of epidemiological studies focusing on TB treat-
ment outcomes in homeless populations [29–31]; few
studies have addressed the impact of homelessness on
treatment outcomes, and the available data came from
high-income countries [25, 26].
Brazil is among the 22 countries with the highest
number of TB cases. In 2014, PTB incidence was esti-
mated as 44/100,000 [2]. São Paulo State (SPS) has the
highest number of TB cases in Brazil (~20 %), with an
estimated incidence of PTB of 37.7/100,000 in 2013 [32].
Incidence varies among cities according to size, popula-
tion density and socioeconomic indicators [32–36] with
higher incidences observed in bigger, more crowded cities,
such as Santos (population ~400,000, incidence of 72.7/
100,000) and São Paulo city (population ~ 11,000,000,
incidence of 46.6/100,000) in 2013 [32]. Poorer areas and
vulnerable groups have higher incidences [33, 37], such as
four poor districts (incidence 149.0/100,000) in São Paulo
city [35]. Treatment success for newly diagnosed PTB
cases is around 80 % in SPS, thus not achieving the WHO
goal of 85 % treatment success [2, 32, 38]. Although it is
the wealthiest state in Brazil, the high socioeconomic
heterogeneity and chaotic urbanisation in SPS, may mean
that homelessness plays an important role in the TB
burden [39].
The aim of this study was to determine the association
between homelessness and the unsuccessful outcome of
treatment of newly diagnosed PTB patients in SPS from
2009 to 2013. Our hypothesis is that newly diagnosed
PTB patients with vulnerable conditions are at higher
risk of not achieving treatment success. This study is
justified because evaluations of PTB treatment outcomes
among the homeless are rare; and a rigorous quanti-
tative evaluation of this topic is missing for emerging
countries.
Methods
Study site
The population of Brazil is 200 million, 22 % of whom
(41 million) live in SPS [39]. The state has 645 munici-
palities with distinct characteristics. The Human Devel-
opment Index (HDI) ranges from 0.639 to 0.862, and
within the main city (São Paulo), the HDI ranges from
0.245 to 0.811. In 2003, a study reported that 27 % of
the population of SPS lived in poverty, with marked
income inequality (Gini index = 0.45) [39]. In Brazil, TB
treatment is fully covered by the public health system.
In SPS, following the National TB Program, directly ob-
served therapy (DOT) is recommended for all patients.
However, the final decision is shared between patients
and multidisciplinary health staff [38]. DOT can bring
additional support during treatment, such as food and
transport vouchers [38, 40]. Although the national guide-
lines strongly recommend DOT for vulnerable groups
such as homeless patients, there is no specific campaign
to support its use among the homeless.
Study design
A historical cohort from the routine electronic SPS TB
database for 2009-2013 was studied.
Study population
Newly diagnosed adult patients with PTB only. We in-
cluded patients aged ≥15 years, who had never been treated
for TB or who had taken anti-TB drugs ≤1 month (i.e. new
TB cases) [2]. Before 2010, the Brazilian-TB Program
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considered patients treated more than five years earlier as
new cases [38]. For the purpose of this study, only the first
TB treatment was considered [2]. The “anatomical defin-
ition” of PTB from WHO includes patients with PTB
associated with extra-pulmonary TB (EPTB) or miliary TB
[41–43]. In order to have a homogenous population of
new cases, we selected patients with PTB only.
We excluded presumptive TB patients whose diagno-
sis had changed during the follow-up period (i.e. they
were not TB cases). We also excluded cases diagnosed
and notified after necropsy (i.e. they would not have
received treatment). Although the WHO “cohort defin-
ition” [41] includes patients with TB who died for any
reason before or after starting treatment, we excluded
patients diagnosed at necropsy because the study aim is
to evaluate treatment success [11]. Finally, we excluded
patients still on treatment at the moment of database
acquisition.
Exposure
A patient was considered homeless if they were without
a fixed, regular, and adequate night-time residence at
PTB notification or when treatment started. This defin-
ition includes individuals who live in emergency shelters/
direct access hostels and those who live in places not
meant for human habitation.
Outcome
We used the 2013 WHO definitions to guide our main
treatment outcome definitions [41], and adapted them to
the SPS dataset. This classification consists of six out-
comes, grouped into treatment success (cured or treatment
completed) and unsuccessful outcome of treatment (treat-
ment failure, death, loss to follow-up and not evaluated).
We chose “unsuccessful outcome of treatment” as our
primary outcome because we planned a pragmatic evalu-
ation of a routine database.
Confounding factors and interactions
Based on the literature, and on a theoretical framework,
we selected potential confounders a priori to be adjusted
for in order to obtain adjusted estimates of the impact of
homelessness on PTB treatment outcome. Confounding
factors included: age, gender, country of birth, race,
education level, alcohol and drug use, diabetes mellitus,
mental disorder, immunosuppression other than HIV,
place of diagnosis, chest x-ray and microbiologic status
at diagnosis, initial drug scheme and DOT.
For biological reasons, HIV is a major determinant of
TB treatment outcome and we pre-specified that HIV is
a strong effect modifier. We used the WHO 2013 defin-
ition [41], classifying HIV as positive, negative or unknown
status (when the patient’s HIV status had been determined
after notification, HIV status is routinely reclassified in the
database).
Data sources
The SPS-TB Program has had a specific strategy to
improve its surveillance system since 1993. In this pro-
ject we used the dedicated electronic system “TBweb”
[44]. Since its inception, the SPS-TB Program has
invested in the quality of data entry and maintenance of
the consistency and validity of data. For instance, there
is continuous audit and feedback, promotion of cam-
paigns and rewarding of units for good data quality. We
included data from 1 January 2009 to 31 December 2013
(dates of notification). The data were extracted on 31
October 2014.
Plan of analysis
Sample size
SPS has 18,000-20,000 TB cases per year, totalling around
90,000-100,000 cases in our cohort [32]. Based on the TB
Program reports, the estimated prevalence of homeless-
ness among cases of tuberculosis is 2.5 % [32]. With 90 %
power, type I error 5 % and 20 % unsuccessful outcome
of treatment among those not homeless, our required
sample size to evaluate the effect of homelessness was
3835 patients assuming 35 % or more poor treatment
outcomes among the homeless. Sample size was calcu-
lated in Epi Info 7 (CDC-USA), using Fleiss with con-
tinuity correction [45].
Descriptive analysis
We described the patients’ general characteristics, showing
the prevalence distribution of each variable. Categorical
variables are shown as percentages and compared using
the Fisher’s exact test or a χ2 test. For the exposure and
primary outcome, we calculated their point-estimate
measure and its 95 % confidence interval (CI) using the
exact method.
Univariate and adjusted analysis
We used logistic regression models to evaluate the effect
of homelessness on treatment outcome. Our main analysis
was based on complete case analysis and we ran a sensitiv-
ity analysis using multiple imputation to deal with missing
data.
We fitted univariate logistic regression models for the
exposure and each potential confounding factor. To
obtain an adjusted estimate of the association between
homelessness and PTB treatment, we fitted a multivariate
logistic regression. To build the final model, we included
all a priori selected potential confounders. We also ran an
additional final model to explore the interaction between
homelessness and HIV status.
Ranzani et al. BMC Medicine  (2016) 14:41 Page 3 of 13
To conduct the multiple imputation, we first inves-
tigated the patterns of missing variables. We assumed
the missing values to be missing at random (MAR)
and explored whether they were conditioned on observed
variables, suggesting a MAR mechanism [46].
We used a multivariate normal model and imputed
the variables age, country of birth, race, education, place
of diagnosis, chest x-ray, microbiologic status and DOT.
We followed the recommended steps to build the imputed
model [46], including all variables used in the final model
as regular variables and the outcome. We also used auxil-
iary variables (year of notification, administrative region)
and passive terms (HIV interaction). We generated five
imputed datasets and, after the imputing process, we
converted the continuous variables to categorical variables
by “adaptive rounding” [47]. We combined the results
using Rubin’s rule [48] and checked the convergence of
the simulations by analysing the worst linear function
(WLF) over successive iterations.
For all logistic regression models, we tested the hypoth-
esis using likelihood ratio tests. For 95 % CI, we used the
quadratic approximation of the log likelihood (Wald
intervals). For the logistic regression models fitted in
the multiple imputed data, we used Wald tests. In the
fully-adjusted models, multicollinearity was assessed
by the amount of variation on the standard errors of
parameters on the logarithmic scale, comparing the
model with and without the variable of interest.
We estimated the population attributable fraction (PAF)
of vulnerable conditions from the final multivariate model
by using the standard formula:
PAF ¼ p0 θ−1
θ
where p’ was the proportion of cases exposed and θ was
the OR from the multivariable model.
All analyses were conducted in STATA 13.1 (StataCorp-Texas).
Further definitions and additional methodology are
given in the online supplementary material (Additional
file 1: eTable 1) [2, 41].
Results
The flowchart is shown in Fig. 1. Of 93,259 adult TB
patients, we excluded 16 % (15,003) because of previous
treatment, 1 % (886) because they were diagnosed at
necropsy and 0.5 % (459) because they were still on
treatment. From the remaining 76,911 patients, we
excluded 19.6 % (15,094) because they had EPTB.
Therefore, we analysed 61,817 newly diagnosed patients
with PTB only.
General characteristics of the homeless
The prevalence of homelessness among PTB patients was
2.8 % (95 % CI 2.7-2.9 %; 1726/61,817). The majority of
cases who were homeless were observed in big cities: four
Fig. 1 Study flow-chart
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cities with more than 750,000 inhabitants had 5.5 %
(1305/23,558) prevalence of homelessness and comprised
76 % (1305/1726) of all cases who were homeless.
General characteristics are reported in Table 1. Home-
less patients were more frequently middle-aged males
(ratio male/female of 6.75), black/brown skin colour, and
less educated (P < 0.001, for all). The prevalence of alcohol
and drug use was three times more frequent in homeless
patients (43.2 % vs. 14.4 %, 30.2 % vs. 9.4 %, P < 0.001,
respectively). There was a marked intersection between
homelessness and alcohol and/or drug use (Fig. 2).
Diabetes mellitus was present in 6.3 % of patients, while
mental disorders and “other immunosuppression” had a
very low prevalence (1.9 % and 0.7 %, respectively). The
prevalence of all such comorbidities was lower in the
homeless patients, except for mental disorders. Overall,
HIV testing was high (~85 %), but homeless patients were
less frequently tested. The prevalence of HIV positivity
was twice as high among homeless cases (17.3 % vs. 8.5 %,
P < 0.001).
Almost two thirds of patients were diagnosed outside
hospitals. However, homeless individuals were frequently
diagnosed at emergency services (34.7 %) (P < 0.001). In
terms of chest x-rays at diagnosis, 76.4 % had positive
findings for PTB. Microbiologic confirmation diagnosis
occurred more frequently among the homeless (91.6 %
vs. 84.8 %, P < 0.001). The majority of patients (approxi-
mately 80 %) were treated with the four drugs scheme
(RHZE). DOT was offered to 73.5 % of patients overall
and to 69.6 % of homeless patients (P < 0.001).
Homelessness and treatment outcomes
The treatment outcomes are shown in Table 2. The per-
centage of treatment success among all cases was high:
81.4 % (95 % CI, 81.1-81.7). Among homeless patients
the percentage of unsuccessful outcome of treatment
was 57.3 % (OR 6.32, 95 % CI 5.73-6.97, P < 0.001). Loss
to follow-up (39.0 %) and death (10.5 %) were the main
problems.
After full adjustment, our model in the complete case
analysis evaluated 36,604 (59 %) patients, as shown in
Table 3. Homelessness remained strongly associated with
poor outcomes (aOR 4.96, 95 % CI 4.27-5.76, P < 0.001).
The influence of age in the unsuccessful results of treat-
ment was non-linear, with older patients being associ-
ated with higher odds of poor outcomes (P < 0.001).
Being male, non-white and non-Brazilian were associ-
ated with worse outcomes. Higher level of education was
non-linearly associated with better outcomes, with strong
protective impact after eight years of education. Alcohol
and drug use had a marked effect on unsuccessful out-
comes of treatment (aOR 1.33, 95 % CI 1.23-1.44, P < 0.001
and aOR 2.06, 95 % CI 1.89-2.24, P < 0.001, respectively).
After adjustment, diabetes mellitus, mental disorders and
other immunosuppression showed no evidence of associ-
ation with unsuccessful outcomes of treatment. Patients
diagnosed at emergency services or when hospitalized had
worse outcomes (aOR 1.54, 95 % CI 1.44-1.65 and aOR
1.89, 95 % CI 1.73-2.06, P < 0.001, respectively). Analysis of
chest x-ray pattern at diagnosis showed that patients with
cavitation had better outcomes than patients who did not
have a chest x-ray. Patients with confirmed microbiological
diagnosis had an aOR of 0.92 (95 % CI 0.85-1.00, P =
0.048) for unsuccessful outcomes of treatment. Finally,
patients who received the recommended drugs (triple until
2009 or quadruple after 2010) and those who received
DOT had better outcomes. There was no evidence of mul-
ticollinearity in the final model.
Sensitivity analysis in multiple imputed data
We observed missing values for eight variables: age
(<0.1 %), DOT (0.9 %), place of diagnosis (1.5 %),
chest x-ray (4.6 %), microbiologic status (5.2 %), race
(15.5 %), country of birth (16.2 %) and education
level (19.5 %). The multiple imputation process had
good convergence as evaluated by the WLF.
Homelessness remained strongly associated with unsuc-
cessful outcome of treatment (aOR 4.81, 95 % CI 4.33-
5.35, P < 0.001) after full adjustment in multiple imputed
analyses (Additional file 1: eTable 2). There were almost
no changes in the point-estimate values for aORs com-
pared with the complete case analysis. However, some
covariates presented strong evidence of association not
observed in the complete case analysis, such as diabetes
mellitus, other immunosuppression and microbiologic
diagnosis (Additional file 1: eTable 2).
Interaction with HIV status
For the evaluation of the interaction effect on the fully
adjusted model, we used the multiple imputed datasets
to increase power. HIV status had a marked effect modi-
fication for homelessness (Pinteraction < 0.001 for inter-
action), changing its association among HIV positive
patients (aOR 2.45, 95 % CI 1.90-3.16) (Fig. 3, Additional
file 1: eTable 3).
Population attributable fraction-PAF
From the final model of the complete case analysis, we
estimated the PAF for homelessness. Because homeless-
ness was strongly associated with alcohol and drug use
(Table 4), we estimated a joint PAF for these three factors.
When combined, their PAF totalled nearly 20.0 %.
Discussion
Our study showed that 2.8 % (95 % CI 2.7-2.9 %) of
newly diagnosed PTB patients in SPS during 2009-2013
were homeless. Homelessness had a marked association
with unsuccessful outcome of treatment (aOR 4.96,
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Table 1 Comparison of general characteristics of newly diagnosed pulmonary TB patients who were homeless and those who were not
Values Overall Not Homelessness Homelessness P value
(n = 61817) (n = 60091) (n = 1726)
Age, years 15-25 12734 (20.6 %) 12616 (21.0 %) 118 (6.9 %) <0.001
25.1-35 16733 (27.1 %) 16301 (27.2 %) 432 (25.1 %)
35.1-45 11951 (19.4 %) 11417 (19.0 %) 534 (31.0 %)
45.1-55 10215 (16.5 %) 9794 (16.3 %) 421 (24.5 %)
55.1-65 6010 (9.7 %) 5833 (9.7 %) 177 (10.3 %)
65.1-75 2719 (4.4 %) 2683 (4.5 %) 36 (2.1 %)
75.1-85 1170 (1.9 %) 1168 (2.0 %) 2 (0.1 %)
85.1-105 230 (0.4 %) 229 (0.4 %) 1 (0.1 %)
Missing 55 (0.1 %) 50 (0.1 %) 5 (0.3 %)
Gender Female 17245 (27.9 %) 17023 (28.3 %) 222 (12.9 %) <0.001
Male 44572 (72.1 %) 43068 (71.7 %) 1504 (87.1 %)
Country of birth Brazil 50410 (97.2 %) 49151 (97.2 %) 1259 (98.7 %) 0.002
Not-Brazil 1423 (2.8 %) 1406 (2.8 %) 17 (1.3 %)
Missing 9984 (16.2 %) 9534 (15.9 %) 450 (26.1 %)
Race White 26931 (51.6 %) 26396 (51.9 %) 535 (38.4 %) <0.001
Black 6106 (11.7 %) 5819 (11.5 %) 287 (20.6 %)
Mixed/Brown 18180 (34.8 %) 17615 (34.7 %) 565 (40.5 %)
Asian 556 (1.1 %) 549 (1.1 %) 7 (0.5 %)
Indigenous 444 (0.9 %) 443 (0.9 %) 1 (0.1 %)
Missing 9600 (15.5 %) 9269 (15.4 %) 331 (19.2 %)
Education Illiterate 1955 (3.9 %) 1886 (3.9 %) 69 (5.9 %) <0.001
1-3 years 6122 (12.3 %) 5920 (12.2 %) 202 (17.3 %)
4-7 years 19178 (38.5 %) 18651 (38.4 %) 527 (45.0 %)
8-11 years 18155 (36.5 %) 17821 (36.7 %) 334 (28.5 %)
12-14 years 3034 (6.1 %) 3005 (6.2 %) 29 (2.5 %)
> = 15 years 1327 (2.7 %) 1317 (2.7 %) 10 (0.9 %)
Missing 12046 (19.5 %) 11491 (19.1 %) 555 (32.2 %)
Alcohol No 52430 (84.8 %) 51450 (85.6 %) 980 (56.8 %) <0.001
Yes 9387 (15.2 %) 8641 (14.4 %) 746 (43.2 %)
Diabetes mellitus No 57955 (93.7 %) 56279 (93.6 %) 1676 (97.1 %) <0.001
Yes 3862 (6.3 %) 3812 (6.4 %) 50 (2.9 %)
Drug users No 55639 (90.0 %) 54434 (90.6 %) 1205 (69.8 %) <0.001
Yes 6178 (10.0 %) 5657 (9.4 %) 521 (30.2 %)
Mental disorder No 60673 (98.1 %) 58999 (98.2 %) 1674 (97.0 %) <0.001
Yes 1144 (1.9 %) 1092 (1.8 %) 52 (3.0 %)
Other immunosuppression No 61379 (99.3 %) 59656 (99.3 %) 1723 (99.8 %) 0.007
Yes 438 (0.7 %) 435 (0.7 %) 3 (0.2 %)
HIV status Negative 47389 (76.7 %) 46399 (77.2 %) 990 (57.3 %) <0.001
Positive 5391 (8.7 %) 5093 (8.5 %) 298 (17.3 %)
Unknown 9037 (14.6 %) 8599 (14.3 %) 438 (25.4 %)
Place of diagnosis PHC/Ambulatory 40110 (65.9 %) 39199 (66.3 %) 911 (53.2 %) <0.001
Emergency service 13255 (21.8 %) 12661 (21.4 %) 594 (34.7 %)
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95 % CI 4.27-5.76, P < 0.001) after adjusting for several
confounding factors; we found similar results in the
multiple imputed data analysis. Losses to follow-up and
deaths were the main poor outcomes for the homeless.
Homelessness, alcohol use and drug use had a joint PAF
of ~20 %. Interestingly, HIV status exerted an effect
modification on the association between homelessness
and unsuccessful outcome of treatment.
Unsuccessful outcome of treatment among homeless
patients was very high (57.3 %) in our analysis, compar-
able to a cohort study in London in 2003 [26]. The
association of homelessness with poor outcomes has
Table 1 Comparison of general characteristics of newly diagnosed pulmonary TB patients who were homeless and those who were not
(Continued)
Hospital 7499 (12.3 %) 7293 (12.3 %) 206 (12.1 %)
Missing 953 (1.5 %) 938 (1.6 %) 15 (0.9 %)
Chest x-ray Not done 9409 (15.2 %) 9075 (15.8 %) 334 (20.9 %) <0.001
Normal 2107 (3.4 %) 2049 (3.6 %) 58 (3.6 %)
Additional pathology 245 (0.4 %) 237 (0.4 %) 8 (0.5 %)
Suggestive of TB 35221 (57.0 %) 34295 (59.8 %) 926 (58.0 %)
Cavitation 11995 (19.4 %) 11725 (20.4 %) 270 (16.9 %)
Missing 2840 (4.6 %) 2710 (4.5 %) 130 (7.5 %)
Microbiological status Negative 8787 (15.0 %) 8647 (15.2 %) 140 (8.4 %) <0.001
Positive 49844 (85.0 %) 48318 (84.8 %) 1526 (91.6 %)
Missing 3186 (5.2 %) 3126 (5.2 %) 60 (3.5 %)
Initial drug scheme Other 1361 (2.2 %) 1232 (2.1 %) 129 (7.5 %) <0.001
RHZ 11356 (18.4 %) 11101 (18.5 %) 255 (14.7 %)
RHZE 49100 (79.4 %) 47758 (79.5 %) 1342 (77.8 %)
Directly observed treatment-DOT No 16219 (26.5 %) 15724 (26.4 %) 495 (30.4 %) <0.001
Yes 45050 (73.5 %) 43918 (73.6 %) 1132 (69.6 %)
Missing 548 (0.9 %) 449 (0.8 %) 99 (5.7 %)
PHC primary health clinics, R rifampicin, H isoniazid, Z pyrazinamide, E ethambutol
Fig. 2 Intersection between homelessness, alcohol use and drug use
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been strong in developed countries [42, 49–52], achiev-
ing an aOR of 9.91 (95 % CI 4.38-22.38) in an Italian
cohort with 3.8 % (60/1564) prevalence of homeless-
ness [53]. In contrast, a Spanish cohort showed no
association between homelessness (prevalence ~2.1 %)
and poor outcomes after adjustment for predominating
age, alcohol use, drug use, immigration and HIV status
[54]. In terms of low- and middle-income countries, a
study in Nicaragua showed that homelessness was associ-
ated with loss to follow-up (n = 502, aOR 3.00, 95 % CI
1.44-6.23) [55]. In a small cross-sectional study from
Colombia which analysed deaths in TB patients, home-
lessness was present in 22 % (12/55) of cases, the majority
being diagnosed at hospital, suggesting late diagnosis [56].
Two overlapped population-based cohorts from the
USA (1994-2003 and 1994-2010), similar in approach to
our study, reported a prevalence of homelessness around
6 % among TB cases [24, 25]. Homeless cases had char-
acteristics comparable to our cohort: young adult males,
high prevalence of alcohol and drug abuse and high
prevalence of HIV positivity. In the 1994-2003 cohort,
treatment success was 77 % for homelessness vs. 84 %
for non-homelessness. DOT coverage was 86 % and
homeless patients who received DOT were more likely
to complete treatment [25]. In the 1994-2010 cohort,
homelessness had twice the odds for unsuccessful out-
come of treatment [24]. Both USA cohorts included
PTB, EPTB and re-treatment cases. Although there were
similarities with our population, homelessness was asso-
ciated with unsuccessful outcome of treatment to a
much lower degree in the USA. Improved social support
[24, 25, 27, 57] and campaigns to improve housing during
treatment [58] could explain these differences and show
that the challenge of successful treatment of tuberculosis
among the homeless can be met.
Our final model was generally consistent with the
literature, highlighting the impact of important features
on TB treatment outcomes. Diabetes mellitus was asso-
ciated with better outcomes in the multiple imputed
analysis, although in the literature it has been associated
with death and treatment failure [20]. We believe that
putting together all the “undesired outcomes” as unsuc-
cessful outcome of treatment, we were unable to observe
this association, as diabetes would decrease cure and
increase mortality but not increase loss to follow-up. In
fact, diabetes patients are likely to be followed up for
medical treatment. The influence of microbiological
confirmation [12, 15, 19] and chest x-ray [12] are con-
troversial, with studies showing different associations
for TB outcomes. Interestingly, we found that the effect
of homelessness was less pronounced among HIV posi-
tive patients. We hypothesized that for these patients,
PTB treatment was prioritized, leading to better man-
agement and follow-up by the TB and HIV-AIDS pro-
gram than for HIV negative or unknown groups.
This study analysed a large dataset that covers all of
SPS (41 million inhabitants). We followed our a priori
plan of analysis, using multiple imputation to deal with
missing data. We estimated the PAF for vulnerable con-
ditions, a cornerstone of public health decisions. Few
studies have addressed this issue, although PAF is funda-
mental to addressing the “social face” of TB [2, 3, 23].
Assuming a causal association between lower treatment
success and homelessness, alcohol use and drug use, we
estimated around 20 % of unsuccessful outcome of treat-
ment in our population would be prevented if we could
eliminate these exposures, or the increased risk associ-
ated with them.
The study has some limitations. First, the ascertain-
ment of homelessness is unlikely to have false-positives.
However, we cannot be confident that no patients pre-
tended not to be homeless for reasons of stigmatisation.
Therefore, we could have underestimated the prevalence
and the impact of homelessness in our study. Second,
we analysed only newly diagnosed PTB, which strength-
ened our internal validity but could have decreased our
perception of the TB burden due to homelessness.
Indeed, it is likely that homelessness prevalence is higher
among relapses, re-treatments and other clinical forms
of TB. Our aim was to provide data to plan interven-
tions; therefore, we restricted our analysis to pulmonary
cases, which are responsible for most transmission and
Table 2 Treatment outcomes among 61,817 newly diagnosed PTB and their distribution among patients who were homeless and
those who were not
Treatment outcomesa Overall Not Homelessness Homelessness P value
(n = 61817) (n = 60091) (n = 1726)
<0.001
Treatment success 50302 (81.4 %) 49565 (82.5 %) 737 (42.7 %)
Treatment failure 374 (0.6 %) 367 (0.6 %) 7 (0.4 %)
Death 3800 (6.2 %) 3619 (6.0 %) 181 (10.5 %)
Loss to follow-up 6307 (10.2 %) 5633 (9.4 %) 674 (39.0 %)
Not evaluated 1034 (1.7 %) 907 (1.5 %) 127 (7.4 %)
aTreatment outcome definitions are in the online material
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Table 3 Fully adjusted estimates for the association between homelessness and unsuccessful outcome of treatment of newly
diagnosed PTB by logistic regression model (n = 36,604, complete case analysis)
Values Adjusted OR (95 % CI) P value
Exposure Homelessness No Reference <0.001
Yes 4.96 (4.27-5.76)
Adjusted for Age, years 15-25 Reference <0.001
25.1-35 1.01 (0.93-1.10) Pdep < 0.001
35.1-45 0.93 (0.85-1.02)
45.1-55 0.84 (0.76-0.93)
55.1-65 0.94 (0.83-1.06)
65.1-75 1.08 (0.92-1.27)
75.1-85 1.92 (1.56-2.36)
85.1-105 2.47 (1.62-3.76)
Gender Female Reference <0.001
Male 1.32 (1.23-1.41)
Country of birth Brazil Reference <0.001
Not-Brazil 2.09 (1.74-2.51)
Race White Reference 0.001
Black 1.16 (1.06-1.28)
Mixed/Brown 1.08 (1.01-1.15)
Asian 0.82 (0.59-1.13)
Indigenous 1.48 (1.10-1.99)
Education Illiterate Reference <0.001
1-3 years 1.04 (0.88-1.23) Pdep < 0.001
4-7 years 1.07 (0.92-1.25)
8-11 years 0.84 (0.72-0.99)
12-14 years 0.57 (0.46-0.70)
> = 15 years 0.62 (0.48-0.81)
Alcohol No Reference <0.001
Yes 1.33 (1.23-1.44)
Diabetes mellitus No Reference 0.173
Yes 0.92 (0.81-1.04)
Drug users No Reference <0.001
Yes 2.06 (1.89-2.24)
Mental disorder No Reference 0.441
Yes 1.10 (0.87-1.38)
Other immunosuppression No Reference 0.144
Yes 1.29 (0.92-1.79)
Place of diagnosis PHC/Ambulatory Reference <0.001
Emergency service 1.54 (1.44-1.65)
Hospital 1.89 (1.73-2.06)
Chest x-ray Not done Reference <0.001
Normal 0.96 (0.80-1.15)
Additional pathology 1.07 (0.64-1.79)
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the main burden of TB. Third, we applied the WHO
definition for HIV status, which could be an issue be-
cause “HIV unknown” would include both positive and
negative patients [17]. However, this was less important
because of the high HIV testing in our population. The
factors beyond not testing for HIV in PTB patients
should be further explored. Fourth, by grouping the
negative outcomes as unsuccessful outcome of treat-
ment, we were not able to differentiate the effect on
specific negative outcomes. The pragmatic approach of
our analysis using routine data to inform stakeholders
justifies our analysis; however, we believe that TB out-
comes definitions and means of analysing them should
be improved.
To improve TB health care for vulnerable groups is a
difficult task which requires multifaceted interventions
[22, 31, 59], involving governmental and community ac-
tions. There are several barriers, from finance to human
support [59]. Indeed, adherence to TB treatment is strongly
influenced by disease awareness and stigmatisation [30].
Table 3 Fully adjusted estimates for the association between homelessness and unsuccessful outcome of treatment of newly
diagnosed PTB by logistic regression model (n = 36,604, complete case analysis) (Continued)
Suggestive of TB 1.04 (0.95-1.14)
Cavitation 0.86 (0.78-0.96)
Microbiologic status Negative Reference 0.048
Positive 0.92 (0.85-1.00)
Initial drug scheme Other Reference <0.001
RHZ 0.73 (0.59-0.91)
RHZE 0.65 (0.53-0.80)
Directly observed treatment-DOT No Reference <0.001
Yes 0.45 (0.42-0.48)
OR odds ratio, CI confidence interval, Pdep test for departure from linearity, PHC primary health clinics, R rifampicin, H isoniazid, Z pyrazinamide and E ethambutol
Fig. 3 Effect modification by HIV status on the association between homelessness and the unsuccessful outcome of pulmonary TB treatment.
Results from the fully adjusted model (adjusted for age, gender, country of birth, race, education level, alcohol and drug use, diabetes mellitus,
mental disorder, immunosuppression other than HIV, place of diagnosis, chest x-ray and microbiologic status at diagnosis, initial drug scheme
and directly observed-treatment-DOT) in the multiple imputed datasets. P value for interaction < 0.001 (Additional file 1: eTable 3)
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Additionally, TB treatment is associated with high direct/
indirect costs [6], as social support is needed to achieve
compliance [4]. Some interventions have had promising
results for LTBI treatment in homeless patients, in addition
to nurse case management with educational programs and
incentives [60] and monetary incentives alone [61, 62]. For
PTB treatment, focus on DOT strategy together with incen-
tives at each visit and bonuses after completion were associ-
ated with positive results in the USA [8, 27]. In Japan, the
combination of DOT with social support was associated
not only with better outcomes but also empowerment of
homeless patients [63].
Brazil has a national universal health coverage system
and TB treatment is fully provided for free by the TB
Program. Important improvements in the program have
been made, although a special focus on the homeless is
needed. We observed a high proportion of homeless pa-
tients being diagnosed at hospitals. Together with other
important factors for poor outcomes, we propose that
homeless patients are more likely to have delayed diag-
nosis and worse access to health care [64]. Active case
finding in the homeless population and at shelter admis-
sion could be an effective strategy to tackle delayed diag-
nosis [65]. Furthermore, we observed that the proportion
of homeless patients who received DOT was lower than
non-homeless patients, although we had expected the
contrary. The implementation of a specific campaign
for DOT among the homeless, additionally providing
socio-economic support might be a feasible and ef-
fective strategy to achieve better treatment outcomes
in this vulnerable group [27, 57]. Structural and social
transformations are necessary, improving not only TB
treatment, but decreasing TB incidence in this popu-
lation. Conditional cash transfer programs [66], food
provision during treatment [40] and mobile health units
for care of the homeless are promising in this setting [67].
Vulnerable conditions are so important for TB that
guidelines and policy reports have launched specific doc-
uments for vulnerable groups [29, 30]. It is important to
discuss the ethical issues surrounding TB, vulnerable
groups and the implemented strategies [68].
Conclusions
In our study we reported the main features of PTB
among the homeless and found evidence that homeless-
ness plays an important role in the PTB burden in a
middle-income country such as Brazil. We believe that
specific local policies dedicated to this vulnerable group
and TB are fundamental and should be further discussed
and implemented.
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Homelessness Alcohol Drug users Number (%) Odds ratio to unsuccessful
outcome of treatment
Proportion among unsuccessful
outcome of treatment -%
PAF for unsuccessful
outcome of treatment -%
No No No 48171 (77.9 %) Reference 65.0 %
No No Yes 3279 (5.3 %) 2.33 7.7 % 4.4 %
No Yes No 6263 (10.1 %) 1.52 12.3 % 4.2 %
No Yes Yes 2378 (3.9 %) 2.56 6.4 % 3.9 %
Yes No No 788 (1.3 %) 6.25 3.9 % 3.3 %
Yes No Yes 192 (0.3 %) 16.7 1.2 % 1.1 %
Yes Yes No 417 (0.7 %) 5.56 1.8 % 1.5 %
Yes Yes Yes 329 (0.5 %) 9.09 1.7 % 1.5 %
PTB pulmonary tuberculosis, PAF population attributable fraction
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